

## **Title page**

### **Title - Management of mild COVID-19: Policy implications of initial experience in India**

Authors - Dr. Rohit Kumar, MBBS<sup>1</sup>, Dr. Bisakh Bhattacharya, MD<sup>1</sup>, Dr. Ved Prakash Meena, MD<sup>1</sup>, Dr. Anivita Aggarwal, MBBS<sup>1</sup>, Dr. Manasi Tripathi, MBBS<sup>2</sup>, Dr. Manish Soneja, MD\*<sup>1</sup>, Dr. Ankit Mittal, MBBS<sup>1</sup>, Dr. Komal Singh, MBBS<sup>1</sup>, Dr. Nishkarsh Gupta, MD<sup>3</sup>, Dr. Rakesh Kumar Garg, MD<sup>3</sup>, Dr. Brajesh Kumar Ratre, MD<sup>3</sup>, Dr. Balbir Kumar, MD<sup>3</sup>, Dr. Shweta Arun Bhopale, MD<sup>3</sup>, Dr. Pavan Tiwari, DM<sup>4</sup>, Dr. Ankit Verma, MD<sup>5</sup>, Dr. Sushma Bhatnagar, MD<sup>3</sup>, Dr. Anant Mohan, PhD<sup>4</sup>, Dr. Naveet Wig, MD<sup>1</sup>, Dr. Randeep Guleria, DM<sup>4</sup>

<sup>1</sup>Department of Medicine, All India Institute of Medical Sciences, New Delhi (110029)

<sup>2</sup>Department of Ophthalmology, All India Institute of Medical Sciences, New Delhi (110029)

<sup>3</sup>Department of Onco-anesthesia & Palliative Medicine, All India Institute of Medical Sciences, New Delhi (110029)

<sup>4</sup>Department of Pulmonary Medicine & Sleep Disorders, All India Institute of Medical Sciences, New Delhi (110029)

<sup>5</sup>Department of Pediatrics, All India Institute of Medical Sciences, New Delhi (110029)

**\*corresponding author**

**Dr. Manish Soneja**

**Additional professor, Department of Medicine, AIIMS**

**Medicine office, 3rd floor, Teaching block, AIIMS, New Delhi (110029)**

**Email id - [manishsoneja@gmail.com](mailto:manishsoneja@gmail.com); Mobile - +91 9013074717**

## **Abstract**

**Objectives** - Ongoing pandemic due to COVID-19 has spread across countries, surprisingly with variable clinical characteristics and outcomes. This study was aimed at describing clinical characteristics and outcomes of admitted patients with mild COVID-19 illness in the initial phase of pandemic in India.

**Design** - Retrospective (observational) study.

**Setting** – COVID facilities under AIIMS, New Delhi, where, isolation facilities were designed to manage patients with mild illness and dedicated COVID ICUs was created to cater patients with moderate to severe illness.

**Participants** - Patients aged 18 years or more, with confirmed illness were eligible for enrolment. Patients who were either asymptomatic or mildly ill at presentation were included. Patients with moderate to severe illness at admission, or incomplete clinical symptomatology records were excluded.

**Methods** - Data regarding demographic profile, comorbidities, clinical features, hospital course, treatment, details of results of RT-PCR for SARS-CoV-2 done at baseline and at day 14, chest radiographs (wherever available) as well as laboratory parameters was obtained retrospectively from the hospital records.

**Main outcome measures** - Final outcome was noted in terms of course of the disease, patients discharged, still admitted (at time of conclusion of study) or death.

**Results** – Out of 231 cases included, majority were males(78.3%) with a mean age of 39.8 years. Comorbidities were present in 21.2% of patients, diabetes mellitus and hypertension being most common. The most common symptoms were dry cough(81, 35%), fever(64, 27.7%), sore throat(36, 15.6%), and dyspnoea(24, 10.4%); asymptomatic infection was noted in 108(46.8%) patients. Presence of comorbidities was an independent predictor of symptomatic disease (OR- 2.66; 95% CI 1.08 to 6.53, p= 0.03). None of the patients progressed to moderate to severe COVID-19. There were no deaths in this cohort.

**Conclusions** - Patients with mild disease at presentation had a stable disease course and therefore such cases can be managed outside hospital setting. A large proportion of patients remained asymptomatic throughout the course of infection and those with comorbidities are more likely to be symptomatic.

**Trial registration** – Not applicable

## **Main Text**

### **Introduction**

The SARS-CoV-2 emerged towards the end of 2019 and since then it has spread across the globe. The coronavirus disease 2019 (COVID-19) pandemic has been raging across different geographies and a wide range of morbidity and mortality rates has been reported from various settings with case fatality rates ranging from 1.8-15%.<sup>(1-3)</sup> This variation can be explained by the age and comorbidity profile of the affected population, testing criteria and admission criteria, besides other factors.<sup>(4-6)</sup> To have a complete understanding of the spectrum of illness, severity of disease and outcomes; studies are required which includes confirmed patients with mild illness and asymptomatic close contacts of positive cases, besides the moderate to severe cases which require hospitalization. This will be useful for policymakers to decide on actions required for control of the pandemic and optimum utilization of healthcare resources in resource-limited settings in particular.

First case of COVID-19 from India was reported on January 30, 2020 from Kerala. The cases in India began rising in the later half of the month of March. The Indian authorities enforced lockdown quite early in the course of the pandemic i.e. on March, 25. Large scale testing and contact tracing was carried out. All patients were admitted irrespective of symptomatology and their close contacts were admitted in isolation facilities and tested for SARS-CoV-2. Subsequently, the guidelines were modified to allow home isolation of very mild/ pre-symptomatics COVID-19 cases. This initial phase presented an unique opportunity to elucidate the disease profile and outcomes among patients presenting with mild symptoms and those diagnosed on contact tracing.

This study was designed to study the clinical characteristics and outcomes including progression to moderate-severe disease among patients with mild COVID-19.

### **Methods**

#### **Study design and setting**

This was a retrospective study conducted in COVID-19 facilities at AIIMS, New Delhi among patients admitted between 20th March and 30th April 2020. It is a tertiary care teaching hospital wherein, facilities for management of COVID-19 patients were created. Isolation facilities were designed to manage patients with mild illness and a dedicated COVID ICU was created to cater patients with moderate to severe illness. Patients presenting to the facility included those with varying degrees of disease severity as well as asymptomatic close contacts of a large congregation, wherein a number of positive cases were reported.

### Procedures

The clinical case records of all admitted patients with laboratory-confirmed COVID-19 were screened for eligibility. The diagnosis was confirmed by real-time reverse-transcriptase- polymerase-chain-reaction (RT-PCR) for detection of SARS CoV-2 on the specimens obtained from nasal and throat swabs. Patients of age more than 18 years and asymptomatic/ mild illness at presentation were included. Patients with incomplete records of clinical symptomatology were excluded. Patients were classified as having mild disease if they presented with uncomplicated upper respiratory tract viral infection with non-specific symptoms such as fever, fatigue, cough, etc or features of pneumonia but no signs of severe pneumonia and no need for supplemental oxygen.<sup>(7)</sup>

Data regarding demographic profile, comorbidities, clinical features, laboratory parameters, hospital course and treatment outcomes were noted. The daily symptom screen included fever, cough, sore throat, shortness of breath, expectoration, rhinorrhoea, myalgia, fatigue, loose stools, chest pain, anorexia, loss of taste and loss of smell and other symptoms as given by the patients. Patients who did not have any symptoms related to COVID-19 at admission or during the hospital course were considered asymptomatic. Details of results of RT-PCR for SARS-CoV-2 done at baseline and at day 14 was obtained retrospectively from the hospital records. Chest radiographs (wherever available) as well as available laboratory parameters were assessed for any abnormality.

Patients were managed as per the national guidelines.<sup>(8)</sup> In case of clinical deterioration, the protocol was to shift patients to a high dependency unit (HDU)/ intensive care unit

(ICU) for further management. Patients were considered dischargeable after 2 negative SARS-COV-2 RT PCR reports (at least 24 hours apart), performed after at least 7 days of last positive test results. Final outcome was noted in terms of number of patients discharged, patients still admitted (at time of conclusion of study) or death. The permission for the study was obtained from the Institute Ethics Committee.

### Statistical analysis

Data was analysed using STATA 13.0. The data is presented as mean (standard deviation)/ median (interquartile range) and frequency percentage. Normality of data was assessed by Shapiro-Wilk's test. Logistic regression analysis was used to find out independent predictors for symptomatic illness and RT-PCR negativity at 14 days. p-value < 0.05 was considered as statistically significant.

## **Results**

The study was conducted in the initial part of the pandemic when patients irrespective of severity of symptomatology were admitted. A total of 335 laboratory-confirmed COVID-19 patients were admitted to the facility in the study period. Among them, 231 cases were included after applying the inclusion and exclusion criteria (Fig. 1).

Majority were males comprising 78.4% of the cohort with mean age 39.8 years (range 18-73 years) (Table 1). Most patients (205, 88.7%) had a definitive history of contact with a suspected or confirmed case. A significant proportion of the patients (49, 21.2%) had one or more chronic diseases including diabetes mellitus, hypertension, cardiovascular or cerebrovascular disease, chronic lung disease including asthma/ chronic obstructive pulmonary disease /tuberculosis or chronic liver disease. Diabetes mellitus (28, 12.1%) and hypertension (19, 8.2%) were the most common comorbidities noted.

Symptoms specific to COVID-19 were present in 123 (53.2%) of the patients; whereas, 108 (46.7%) patients remained asymptomatic. The median duration of symptoms was 3 days (IQR 2-5.5). Among symptomatics, the most common symptoms included dry cough

(81, 65.8%), fever (64, 52%), sore throat (36, 29.2%) and shortness of breath (24, 19.5%)(Figure 2). The most common presentation among symptomatic patients was with dry cough alone (27, 11.7%). Other common presenting features were fever, fever with dry cough; and fever with cough and shortness of breath (Figure 3). The laboratory abnormalities included anemia in 12.2%, leukopenia in 4.8% and lymphocytopenia (< 1500 cells/cumm) in 11.2% of the patients.

The demographic and laboratory parameters are compared between symptomatic and asymptomatic patients in table 2. Presence of comorbidities emerged as an independent predictor of symptomatic disease with odds ratio of 2.66 (95% CI 1.08-6.53, p= 0.03) on logistic regression analysis.

RT-PCR for SARS-CoV-2 was positive in 14.5% (26/179) of patients at the end of 2 weeks. Table 3 shows the comparison of various demographic, clinical and laboratory parameters among these 2 groups of patients, wherein no statistically significant differences were noted.

Among the 231 cases none progressed to moderate-severe disease during the course of hospitalization. Four patients (1.7%) required shifting to the ward unit to manage comorbidities including angina (1), ureteric colic (1) and glycemic control (2). Overall, 8.1% (4/49) patients with comorbidities required uptriaging. There were no deaths in this cohort.

At the time of writing this manuscript, 172 (74.5%) patients have been discharged and 59 (25.5%) are still admitted.

## **Discussion**

In this retrospective study, 231 admitted patients with mild illness were recruited. The mean age was 40 years and one-fifth had some sort of comorbidities. Cough (65.8%) and fever (52%) were the most common features among symptomatics. A large proportion of patients (46.7%) remained asymptomatic throughout the course of the

infection; patients with comorbidities were more likely to be symptomatic. None of the patients progressed to moderate-severe disease.

The cohort we recruited is younger compared to most studies;<sup>(5,9-12)</sup> but similar in age profile of few reported studies.<sup>(13,14)</sup> This is an important context to interpret the results because increasing age and associated comorbidities are well known risk factors for disease severity and outcomes.<sup>(5,10,15-17)</sup> About one-fifth of our patients had comorbidities which is higher than reported among mild cases in the same age-group from Europe;<sup>(13)</sup> however, it is closer to the reports among higher age-groups from other regions.<sup>(9)</sup> This probably reflects the increased burden of noncommunicable diseases in Indian population.<sup>(18)</sup> Thus our cohort was unique in being younger but with a higher burden of comorbidities compared to other reports of COVID-19.

The reports on symptomatology are varied across geographies. Fever and cough are the most common symptoms reported across various countries.<sup>(9,15,19,20)</sup> In our study cough and fever were the commonest symptoms, with former being more common. It has important implications because patients with mild cough and no fever may ignore their symptoms and not seek medical attention. Further, the frequency of these symptoms were much lower than reported in other studies. In a study from China, the reported frequencies of fever and cough was reported as 88% and 68% respectively, whereas in the United States it was 94% and 88%.<sup>(9,20)</sup> It is in stark contrast to 35% and 28% seen in the present study. It may be related to the diagnostic strategy and admission criteria which is variable across countries. This study was carried out in early days of the pandemic in India when large scale surveillance, testing and contact tracing was carried out. All patients were admitted irrespective of symptomatology and their close contacts were admitted in isolation facilities and tested for SARS-CoV-2. This presented a unique opportunity to study the disease course in all infected patients irrespective of symptomatology.

A significant proportion of our patients were asymptomatic throughout the course of admission. The literature on asymptomatic infections are sparse at present. This is likely due to the fact that these patients would not seek medical care or may have been

treated at home as the healthcare system in most of the countries are overwhelmed due to the large number of patients with moderate-severe disease requiring hospitalization. The proportion of diagnosed asymptomatic infections reported are between 1-19.8%.<sup>(21-25)</sup> The initial reports from China gave a frequency of 1% whereas, a much higher proportion at 19.8% was reported from the Republic of Korea.<sup>(21,26)</sup> Asymptomatic ratio among evacuated Japanese nationals from China is estimated at 30.8%.<sup>(24)</sup> This variation is due to the different strategies of surveillance and testing adopted in various settings. Our findings are similar to another reported study from India, although on a smaller sample size.<sup>(14)</sup> Further, asymptomatic infections were more likely among patients with comorbidities with odds ratio of 2.66. This is consistent with another report of silent infections among young adults without comorbidities.<sup>(25)</sup> The finding of 47% asymptomatic infections in the present study has a bearing on pandemic control strategies.

There is sparse literature on disease course and progression to severe disease among patients with mild disease and asymptomatic infection. In a study from Korea, out-of-hospital cohort treatment of COVID-19 patients with mild symptoms reported disease worsening in 2.3% patients. Patients with severe disease and underlying chronic severe medical conditions were excluded.<sup>(27)</sup> In our study, none of the patients had disease progression to moderate-severe disease. Up triaging was required in 1.7% of the patients due to worsening of the underlying comorbidities. This data is reassuring that COVID-19 patients with mild disease or asymptomatic infections can be managed outside hospital settings. This will help in optimum utilization of healthcare facilities in resource-limited settings facing COVID-19 pandemic. This will also free up precious hospital beds for management of patients with moderate to severe disease.

This study has several limitations. First, there is sparse literature on mild cases and our patients were younger compared to other reported studies, so direct comparison of clinical manifestations and disease progression is to be done cautiously. However, our patients had a significant burden of comorbidities for their age, which is an important risk factor for severe disease. Secondly, this being a retrospective study there are inherent limitations. Daily symptom screen data was lacking in many cases leading to



their exclusion, laboratory data was incomplete particularly with respect to markers like serum ferritin levels and C-reactive protein. Thirdly, there was a selection bias owing to aggressive contact tracing and admission of close contacts for testing. This resulted in a large number of asymptomatic patients being recruited for the study. Nevertheless, to the best of our knowledge, this is the largest report of clinical manifestations and disease course among admitted patients with mild COVID-19 and the data will be useful for policy makers.

## **Conclusion**

Patients with mild disease at presentation have a stable disease course and can be managed outside the hospital setting. Adequate care must be taken for comorbid conditions. A large proportion of patients are asymptomatic throughout the course of infection and patients with comorbidities are more likely to be symptomatic.

## References

1. Li LQ, Huang T, Wang YQ et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. *J Med Virol*. 2020 Mar 12.
2. Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. *J Med Virol*. 2020;10.1002/jmv.25748.
3. CSSE J. Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). 2020-03-15]. <https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6>. 2020.
4. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. *JAMA*. 2020 Apr 6
5. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*. 2020 Mar;395(10229):1054–62.
6. Du R-H, Liang L-R, Yang C-Q, Wang W, Cao T-Z, Li M, et al. Predictors of Mortality for Patients with COVID-19 Pneumonia Caused by SARS-CoV-2: A Prospective Cohort Study. *Eur Respir J*. 2020 Apr 9
7. World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (2019- nCoV) infection is suspected: interim guidance. March 13, 2020 (<https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf>).
8. Revised Guidelines on clinical management of COVID-19. Directorate General of Health Services (EMR division). Ministry of Health & Family Welfare, Government of India. <https://www.mohfw.gov.in/pdf/RevisedNationalClinicalManagementGuidelineforCOVID1931032020.pdf>
9. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*. 2020;382(18):1708–1720.

10. CDC COVID-19 Response Team. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 — United States, February 12–March 28, 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:382-386.
11. Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. *JAMA*. 2020;323(16):1574–1581. doi:10.1001/jama.2020.5394
12. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020;395(10223):507–513
13. Lechien JR, Chiesa-Estomba CM, Place S, et al. Clinical and Epidemiological Characteristics of 1,420 European Patients with mild-to-moderate Coronavirus Disease 2019. *J Intern Med*. 2020;10.1111/joim.13089.
14. Gupta N, Agrawal S, Ish P, et al. Clinical and epidemiologic profile of the initial COVID-19 patients at a tertiary care centre in India. *Monaldi Arch Chest Dis*. 2020;90(1):10.4081/monaldi.2020.1294. Published 2020 Apr 10.
15. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395:497-506.
16. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China *JAMA Intern Med*. 2020;e200994. doi:10.1001/jamainternmed.2020.0994
17. Hu L, Chen S, Fu Y, et al. Risk Factors Associated with Clinical Outcomes in 323 COVID-19 Hospitalized Patients in Wuhan, China. *Clin Infect Dis*. 2020;ciaa539. doi:10.1093/cid/ciaa539
18. Arokiasamy P. India's escalating burden of non-communicable diseases. *Lancet Glob Health*. 2018;6(12):e1262–e1263. doi:10.1016/S2214-109X(18)30448-0
19. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. *JAMA*. 2020
20. Aggarwal S, Garcia-Telles N, Aggarwal G, Lavie C, Lippi G, Henry BM. Clinical features, laboratory characteristics, and outcomes of patients hospitalized with

- coronavirus disease 2019 (COVID-19): Early report from the United States. *Diagnosis (Berl)*. 2020;7(2):91–96. doi:10.1515/dx-2020-0046
21. Kim GU, Kim MJ, Ra SH, et al. Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19. *Clin Microbiol Infect*. 2020;S1198-743X(20)30268-8. doi:10.1016/j.cmi.2020.04.040
22. Hu Z, Song C, Xu C, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. *Sci China Life Sci*. 2020;63(5):706–711. doi:10.1007/s11427-020-1661-4
23. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. *Euro Surveill*. 2020;25(10):2000180. doi:10.2807/1560-7917.ES.2020.25.10.2000180
24. Nishiura H, Kobayashi T, Miyama T, et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). *Int J Infect Dis*. 2020;94:154–155. doi:10.1016/j.ijid.2020.03.020
25. He G, Sun W, Fang P, et al. The clinical feature of silent infections of novel coronavirus infection (COVID-19) in Wenzhou . *J Med Virol*. 2020;10.1002/jmv.25861. doi:10.1002/jmv.25861
26. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72–314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA*. 2020;323(13):1239–1242. doi:10.1001/jama.2020.2648
27. Park PG, Kim CH, Heo Y, Kim TS, Park CW, Kim CH. Out-of-Hospital Cohort Treatment of Coronavirus Disease 2019 Patients with Mild Symptoms in Korea: an Experience from a Single Community Treatment Center. *J Korean Med Sci*. 2020 Apr 6;35(13):e140.

## **Figure legends**

### **Figure 1 Study flow diagram**

**Figure 2 Frequency of common symptoms among COVID-19 patients (n=231)**

### **Figure 3 Symptomatology among COVID-19 patients (n=231)**

**Table 1: Baseline characteristics of COVID-19 patients (n=231)**

Characteristic	n(%)
Age* (in yrs)	39.8 ± 13.6
Age category	
18-40 yrs	125 (54.1)
41-60 yrs	90 (38.9)
> 60 yrs	16 (6.9)
Gender (female)	50 (21.6)
History of contact	205 (88.7)
Comorbidities	49 (21.2)
Diabetes Mellitus	28 (12.1)
Hypertension	19 (8.2)

\*mean ± Standard deviation



**Table 2: Demographic and laboratory parameters among symptomatic and asymptomatic patients (n=231)**

Characteristic	Asymptomatic (n=108)	Symptomatic (n=123)	p-value	Odds ratio	p-value
Age category					
18-40 yrs	62	63			
41-60 yrs	43	47	0.06	0.63-1.9	0.74
> 60 yrs	3	13			
Gender (female)	18	32	0.08	0.25-2.44	0.67
Comorbidities	13	36	0.001	<b>2.66</b> <b>(1.08-6.53)</b>	<b>0.03</b>
Hemoglobin	13.8 ± 1.7	13.5 ± 1.8	0.17	0.73-1.23	0.69
Total leucocyte count	8452 ± 2576	7429 ± 2346	0.005	0.99-1.00	0.05
Absolute lymphocyte count	2377 ± 687	2223 ± 695	0.15	0.33-2.88	0.97
CRP	0.13 (0.08-0.26)	0.29 (0.05-	0.80	-	-

		1.87)			
Ferritin	23 (14.8-59.8)	126 (19.9-240)	0.08	-	-

\*Hemogram available for 188, CRP for 24, Ferritin for 20 patients

**Table 3: Demographic and laboratory parameters among RT-PCR positive and negative patients at the end of 2 weeks (n=179)**

Characteristic	RT-PCR positive (n=26)	RT-PCR negative(n=153)	p-value	Odds ratio	p-value
Age category					
18-40 yrs	13	81	0.77	0.52-2.31	0.80
41-60 yrs	11	61			
> 60 yrs	2	11			
Gender (female)	6	19	0.14	0.10-1.61	0.20
Comorbidities	5	30	0.96	0.20-2.78	0.67
Symptomatic	12	72	0.93	0.43-2.55	0.9

Received HCQ	6	29	0.62	0.41-4.02	0.65
Hemoglobin	13.6 ± 1.9	13.8 ± 1.5	0.59	0.77-1.46	0.7
Lymphopenia (<1500/mm <sup>3</sup> )	2	12	0.97	0.17-6.22	0.97

Confirmed cases screened  
– 335

Excluded (104)  
24 - <18 years of age  
78 – incomplete clinical data  
2 – moderate-severe disease


Cases included in the study – 231


Symptomatic –  
123

RT PCR at day 14

Discharged –172, Still admitted – 59

Frequency





● Asymptomatic ● Cough ● fever + cough ● fever ● fever + cough + shortness of breath ● Others